BCL11A (B-cell lymphoma/leukemia 11A) is a critical zinc-finger transcription factor that acts as the master repressor of fetal hemoglobin (HbF) expression in adult erythroid cells. Targeting the BCL11A pathway represents a revolutionary therapeutic paradigm for hemoglobinopathies, including Sickle Cell Disease (SCD) and $\beta$-thalassemia, as well as select oncological indications.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for BCL11A drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | BCL11A Recombinant Protein (Full-length & DNA-binding domain) High purity (>95%), Endotoxin Controlled. Sequence Verified. |
View BCL11A Products |
| Gene Delivery | BCL11A Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and functional expression. |
View BCL11A Products |
| Benchmark Ab | Anti-BCL11A Recombinant Antibody Recombinant positive control for IP, ChIP, and Western Blot validation. |
View BCL11A Products |
| Validator | BCL11A siRNA Set For target knockdown and downstream HbF (HBG1/2) induction verification. |
View BCL11A Products |
| Related Target A | BCL11B Highly homologous family member; essential for off-target and selectivity screening. |
View BCL11B Products |
| Related Target B | HBG1 Downstream functional readout; fetal hemoglobin subunit gamma-1 marker. |
View HBG1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Homolog Selectivity (BCL11A vs BCL11B) | Sequence-verified recombinant BCL11A and BCL11B proteins available with >95% purity. |
| Intracellular Delivery & Knockdown Validation | Lentivirus and siRNA tools strictly validated for transduction efficiency. |
| Lack of Controls | Clinical Benchmark Antibodies included for binding and epigenetic assays. |
| False Positives | Validated siRNA included for specificity and functional rescue checks. |
Live BCL11A R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for BCL11A therapeutics is intensifying, with major players shifting focus from traditional gene editing to small-molecule degraders (PROTACs/molecular glues) and RNA-targeted therapies. As first-generation ex vivo gene-editing therapies (such as Casgevy) reach the clinic, the next wave of R&D is targeting orally bioavailable small molecules that can disrupt the BCL11A transcription factor complex or induce its degradation, bypassing the need for complex bone marrow transplantation.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Gene Editing (CRISPR/Cas9) | Vertex Pharmaceuticals, CRISPR Therapeutics | Sickle Cell Disease, $\beta$-Thalassemia | Downstream HbF induction validation (Need HBG1/2 verification tools) |
| Targeted Protein Degradation (PROTAC/Glue) | FTO-targeted platforms, Academic Consortia | Hemoglobinopathies, Hematological Malignancies | Selectivity Assay (Need Mutant vs WT Proteins and BCL11B counter-screening) |
| RNA Interference (siRNA) | Alnylam, Silence Therapeutics | Solid Tumors (TNBC), B-cell Lymphomas | In vitro knockdown verification (Need validated siRNA and Lentiviral controls) |